Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide

    Update 11/27/2023
    Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
    View this post in the Community →

    Similar Community Posts Join

    6 / 727 results

    Related Research

    6 / 8 results